A rare genetic condition, Spinal Muscular Atrophy (SMA) affects one in 7,000 people in India. It mostly affects children and ...

The bench said that public good outweighs the company’s profit as the drug is not available at an affordable price in India.

The high court noted that SMA is a debilitating disease which has no cure, and the only approved drug, Risdiplam, marketed ...

Patients with Spinal Muscular Atrophy (SMA) are hopeful of getting access to generic versions of Roche’s patented drug ...

Doctors in the US have treated a fetus with a rapidly progressive congenital disease while in the uterus for the very first ...

The Delhi High Court denied Roche's request to temporarily restrain Natco Pharma from producing its spinal muscular atrophy ...

In a major relief to Indian drugmaker Natco Pharma, the Delhi High Court has rejected an interim injunction plea filed by ...

The Delhi High Court on Monday dismissed an interim injunction application filed by Swiss pharmaceutical giant F Hoffmann-La ...

The high court decision potentially opens the door for access to a generic version of the patented drug - Risdiplam - at a ...

For this single case, the FDA approved the early administration of the oral drug risdiplam, brand name Evrysdi, owned by the pharmaceutical company F. Hoffmann-La Roche AG. Over the years ...

The Delhi High Court has observed that availability of a drug for treatment of rare diseases at economical and competitive ...

So far, the child's lack of symptoms comes as a successful result of the orally administered drug risdiplam, developed by pharmaceutical company Roche, based in Basel, Switzerland. Risdiplam works ...